Cookies help us deliver our services. By using our services, you agree to our use of cookies.

OneChain Immunotherapeutics is a spin-off company from the Josep Carreras Leukemia Research Institute and ICREA, based on research led by Dr. Pablo Menéndez. OneChain aims to develop immunotherapies against haematological neoplasms using CAR-T candidates against different antigens.

Pipeline

OC_1

CART CD1a Immunotherapy against T-ALL

T-ALL comprises 10–15% of all acute leukemias diagnosed in children and 20–25% in adults, with a median diagnostic age of 9 years. Survival of patients with T-ALL treated with intensive chemotherapy remains less than 70%, and relapsed/refractory (r/r) T-ALL has a particularly poor outcome of 6% to 20% in 5 to 10 years. OC_01 is a CART CD1a Immunotherapy developed as a treatment for refractory relapsed patients with cortical T-ALL, a T-ALL subgroup without many options to date.

OC_2

CART CD22 Immunotherapy

B-ALL is the most common cancer in children and despite current 5-year disease-free survival rates of 80%, relapsed/refractory (r/r) patients still have a dismal outcome. B-ALL is less frequent in adults and still associated with unfavorable clinical outcomes. OC_02 immunotherapy, based on a bispecific CART, is an alternative treatment to salvage chemotherapy followed by autologous stem cell transplantation only suitable for 50% of eligible patients with r/r B-ALL.

OC_3

Novel γδ T cells allogeneic platform

Recently, γδ T cells have emerged as an alternative to αβ T cells for cellular immunotherapy. They are not constrained by MHC presentation of tumor‐associated peptides but, providing robust and durable antitumor responses. OneChain platform is a novel and efficient method for a selective, large‐scale generation of human cytotoxic Vδ1+ γδ T cells. They are very attractive candidates for adoptive cell therapy of cancer. Vδ1 naïve cells are produced in a TCR-independent manner and expanded to induce Vδ1+ T cell proliferation, which allows for a significant-fold expansion.

Stage of Development

Product
Indication
Development
Preclinical
Clinical

OC_1 T-ALL

OC_2 B-ALL

OC_3 Allogeneic

Vision

To create a better, healthier world for people with cancer

Mission

To discover, develop and deliver innovative therapeutics for patients suffering from leukemia

Core Values

Integrity Doing What’s Right
Teamwork Working Together
Accountability Taking Personal Responsibility
Excellence Being Your Best

Board of directors

Pablo Menéndez

Pablo Menéndez

Founder and CSO

Pablo Menéndez was awarded a PhD by the University of Salamanca in 2002. He then conducted postdoctoral training (2002-2006) in stem cell biology and childhood leukemia. He returned to Granada as Director of The Andalusian Stem Cell Bank and Principal Investigator at GENyO, a Pfizer-Andalusian Health Department centre for Genomics and Oncology (2007-2013). Since July 2013 he is an ICREA Research Professor and he heads the "Stem cell biology, developmental leukemia and Immunotherapy" group at the Josep Carreras Leukemia Institute-Campus Clinic Hospital-School of Medicine of the University of Barcelona. Pablo Menendez has published 190 peer-review publications with an accumulated impact factor of 1600 (H and i10 factors are 54 and 140, respectively). His work has been cited 10500 times. He has obtained solid competitive national and international research funding, has filed 10 patents in stem cell biology and immunotherapy, and has supervised >30 scientific staff including master, PhD students, postdoctoral scientists and technicians.

Albert Carreras

Albert Carreras

Trustee of Josep Carreras Foundation

Lawyer, entrepreneur and trustee of Josep Carreras International Leukaemia Foundation. In 2010, this non-profit organization launched a ground-breaking project: the Josep Carreras Leukaemia Research Institute, the first European research center exclusively focused in leukaemia and other haematological diseases, and one of the few existing in the world

Luís Pareras

Luís Pareras

Partner InVivo Capital

Luis is an entrepreneur in the healthcare space and founder and partner of Invivo Capital Partners together with Albert Ferrer. He is or has been board member of biotech start-ups Versantis, Peptomyc, Sanifit, Minoryx, N-life, Arthex Biotech, Pulmobiotics, Gyala, Telum Therapeutics, OneChain Immunotherapeutics and Telomere Therapeutics, and advisor to a number of biotechnology and innovation organizations.

Albert Ferrer

Albert Ferrer

Partner InVivo Capital

Degree in Business Administration and MBA from ESADE, Master CEMS in HEC Paris and Chartered Financial Analyst (CFA). He has been involved in the Spanish VC industry for the past 15 years in several companies. Specialist in corporate transactions and asset valuation. He sits in the board of several Life Sciences companies. Founded Invivo Capital Partners together with Luis Pareras.

Jorge Alemany

Jorge Alemany

CEO

Jorge has a long experience in research and management in prestigious institutions such as the NIH in the USA or at the Nactional Cancer Center (CNIO) in Spain. He has work in PharmaGen (today Genómica SAU.), Genetrix and Spherium Biomed. Founder of Cellerix, later Tigenix, that was acquired by Takeda Pharmaceuticals in 2018. Cellerix developed the first Cell Therapy product approved by the EMA.

Team

Pablo Menéndez

Pablo Menéndez

Founder and CSO

Pablo Menéndez was awarded a PhD by the University of Salamanca in 2002. He then conducted postdoctoral training (2002-2006) in stem cell biology and childhood leukemia. He returned to Granada as Director of The Andalusian Stem Cell Bank and Principal Investigator at GENyO, a Pfizer-Andalusian Health Department centre for Genomics and Oncology (2007-2013). Since July 2013 he is an ICREA Research Professor and he heads the "Stem cell biology, developmental leukemia and Immunotherapy" group at the Josep Carreras Leukemia Institute-Campus Clinic Hospital-School of Medicine of the University of Barcelona. Pablo Menendez has published 190 peer-review publications with an accumulated impact factor of 1600 (H and i10 factors are 54 and 140, respectively). His work has been cited 10500 times. He has obtained solid competitive national and international research funding, has filed 10 patents in stem cell biology and immunotherapy, and has supervised >30 scientific staff including master, PhD students, postdoctoral scientists and technicians.

Jorge Alemany

Jorge Alemany

CEO

Jorge has a long experience in research and management in prestigious institutions such as the NIH in the USA or at the Nactional Cancer Center (CNIO) in Spain. He has work in PharmaGen (today Genómica SAU.), Genetrix and Spherium Biomed. Founder of Cellerix, later Tigenix, that was acquired by Takeda Pharmaceuticals in 2018. Cellerix developed the first Cell Therapy product approved by the EMA.

Wilmar Castillo Ávila

Wilmar Castillo Ávila

Project Manager

Wilmar has more than 15 years of biomedical research experience at the University of Barcelona, the pharmaceutical company Ferrer and the Catalan Institute of Oncology. During the last 6 years, she has focused her work on managing pharmaceutical development projects in different therapeutic areas in companies such as AlbaJuna Therapeutics SL and Spherium Biomed SL. As a project manager, she has led and coordinated multifunctional teams to ensure preclinical and clinical projects' progress.

Víctor M. Díaz Cortés

Víctor M. Díaz Cortés

Research Director

With more than 15 years in biomedical and oncological research at the Autonomous University of Barcelona, the Hospital de la Vall d'Hebron, the New York University School of Medicine and the San Raffaele Biomedical Science Park in Milan, and the IMIM-Hospital del Mar. After completing his postdoctoral training, he joined the Universitat Pompeu Fabra as a full professor and later as an assistant, and has recently joined the International University of Catalonia.

Laura García Pérez

Laura García Pérez

Scientist

Biologist graduated at the University of Granada, she did her PhD in Immunology at the section of Molecular Gastroenterology and Immunology of the University Medical Center Hamburg-Eppendorf and the Immunobiology department at Yale University. Her research has focused on the role of T-cell derived cytokines in the context of intestinal inflammation and carcinogenesis. After her first postdoctoral training at the University Medical Center Hamburg-Eppendorf, she is joining OneChain Immunetherapeutics as Scientist

Investors

Contact

info@onechaintx.com
609 149 992
Office

C/Muntaner 383, 3rd 2nd 08021 Barcelona Spain

Laboratory

Josep Carreras Institute Campus Clinic Laboratories Ala Sud, 2nd section, 4th floor Faculty of Medicine of the University of Barcelona C. Casanova 143 08036 Barcelona

Write us an email
info@onechaintx.com